Ken Griffin Protagonist Therapeutics, Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$33.72 - $47.33 $20,232 - $28,398	-600 Reduced 8.11%	6,800 $305,000
Q2 2024 Aug 14, 2024	SELL	$24.66 - $34.8 $86,310 - $121,799	-3,500 Reduced 32.11%	7,400 $256,000
Q1 2024 May 15, 2024	SELL	$21.79 - $32.15 $7.23 Million - $10.7 Million	-331,700 Reduced 96.82%	10,900 $315,000
Q4 2023 Feb 14, 2024	BUY	$14.05 - $23.44 $155,955 - $260,184	11,100 Added 3.35%	342,600 $7.86 Million
Q3 2023 Nov 14, 2023	SELL	$16.68 - $23.66 $281,892 - $399,854	-16,900 Reduced 4.85%	331,500 $5.53 Million
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $920,822 - $1.5 Million	-51,100 Reduced 12.79%	348,400 $9.62 Million
Q1 2023 May 15, 2023	BUY	$10.78 - $25.38 $776,160 - $1.83 Million	72,000 Added 21.98%	399,500 $9.19 Million
Q4 2022 Feb 14, 2023	SELL	$7.36 - $11.17 $75,808 - $115,051	-10,300 Reduced 3.05%	327,500 $3.57 Million
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $1.61 Million - $2.39 Million	-204,500 Reduced 37.71%	337,800 $2.85 Million

248

56.7M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.93B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.